Subscribe
Wednesday, April 22, 2026
33.2 C
Bengaluru
type here...
Subscribe

IMS Health

IMS Health is a leading global information and technology services company providing clients in the healthcare industry with end-to-end solutions to measure and improve their performance.

IMS Health Market Reflection Report for September 2016

IMS Monthly Market Reflection Report IMS Health -
The Indian Pharmaceutical Market (IPM) was valued at Rs. 10,278 crs in the month of September 2016 clocking a strong 10% growth over same period last year (SPLY). On a MAT September basis, the industry was valued at Rs. 111,022 crores and reflected a 13% growth with volumes contributing around 40% of this growth and New Introductions playing an important role with around 38% contribution to the overall growth.

IMS Health Market Reflection Report for August 2016

IMS Monthly Market Reflection Report IMS Health -
The Indian Pharmaceutical Market (IPM) was valued at Rs. 10,426 crores in the month of August 2016 clocking a strong 18% growth over same period last year (SPLY). This was the second consecutive month where the IPM crossed the 10,000 crore mark.

IMS Health Market Reflection Report for July 2016

IMS Monthly Market Reflection Report IMS Health -
The Indian Pharmaceutical Market (IPM) was valued atRs. 10,025 crores in the month of July 2016 clocking a 14.7% growth over same period last year (SPLY). This was the first time ever the market crossed the 10,000 crore mark in a single month.

IMS Health Market Reflection Report for June 2016

IMS Monthly Market Reflection Report IMS Health -
Every month, MedicinMan in partnership with IMS Health, brings our readers the latest industry numbers related to sales and revenues of different companies, brands and therapy areas in the Indian Pharmaceutical Market.
spot_imgspot_img

MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More

Company

Headlines

The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap

0
The Semaglutide Shift: From Blockbuster to Commodity Why the $50...

Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy

0
In 1989, oncology in India was not a business...

Ritesh Desai has joined Standard Chartered India as Executive Director

0
Ritesh Desai has joined Standard Chartered India as Executive...

The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation

0
The story of Healthium is not just one of...

Newsletter

Get important news delivered directly to your inbox and stay connected!

Copyright © 2026 | Crafted by SlamDunk